In recent years, prostate cancer membrane antigen (PSMA), a type II integral membrane glycoprotein that is strongly over-expressed in PCa and minimally detectable in prostate normal tissue, has emerged as an attractive biomarker in the field. Here, FOLH1 is linked to posterior cortical atrophy.